Vir Biotechnology Announces First Patient Dosed In The Phase 2 SOLSTICE Trial Evaluating VIR-2218 And VIR-3434 For The Treatment Of Chronic Hepatitis D Virus Infection
Vir Biotechnology, Inc. (NASDAQ:VIR) today announced that the first patient has been dosed in the Phase 2 SOLSTICE clinical trial evaluating VIR-2218 and VIR-3434 as monotherapy and in combination for the treatment of